Urology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

This email address is being protected from spam bots, you need Javascript enabled to view it

The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients.

A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response.

After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICSI/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement.

In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.

Written by
Porru D, Cervigni M, Nasta L, Natale F, Lo Voi R, Tinelli C, Gardella B, Anghileri A, Spinillo A, Rovereto B.

Reference
Rev Recent Clin Trials. 2008 May;3(2):126-9.

PubMed Abstract
PMID:18474023

UroToday.com IC/PBS/BPS Section

Please log-in or register in order to submit comments.

Powered by AkoComment!